doesn't have a list
of ingredients.

Aimmune develops desensitization treatments to protect people with food allergies by potentially making accidental exposures less dangerous. Learn More

CODIT™ & Oral Immunotherapy

Aimmune is developing treatments for food allergies using our standardized, pharmaceutical-grade food allergens and our characterized oral desensitization immunotherapy, or CODIT™, approach. We built CODIT on a foundation of extensive independent scientific research on oral immunotherapy that shows that most patients with food allergies can become desensitized to the food by ingesting their allergens in gradually increasing amounts and then maintaining a steady daily dose thereafter. We aim to offer standardized products, optimized protocols and robust support services to protect people with food allergies from accidental exposures by achieving clinically meaningful levels of desensitization to food allergens.

Learn More

AR101 for Peanut Allergy

We are conducting our Phase 3 PALISADE trial of our lead product candidate, AR101, for the treatment of peanut allergy, one of the most common food allergies, in peanut-allergic patients ages 4-55 years in the United States, Canada and Europe. We are also working on developing treatments for other common food allergies using standardized, pharmaceutical-grade food allergens and our CODIT™ approach.

Learn More